OS2.5 Effect of rituximab in primary central nervous system lymphoma - results of the randomized phase III HOVON 105/ALLG NHL 24 study

BACKGROUND: use of rituximab in Primary Central Nervous System Lymphoma (PCNSL) is based on extrapolation of its impact on survival rates in systemic diffuse large B-cell lymphoma and phase II and retrospective PCNSL studies. We performed an international intergroup randomized phase III study to inv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Bromberg, J E C, Issa, S, Bakunina, K, Minnema, M C, Seute, T, Cull, G, van den Bent, M J, Gonzales, M, de Jong, D, Doorduijn, J K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Oral Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144287/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados